NEW YORK and ARNHEM, Netherlands, Nov. 28 /PRNewswire-FirstCall/ --
Organon and Pfizer today announced that they have agreed to discontinue
their collaboration in the further development of asenapine, a new drug
candidate for the treatment of schizophrenia and acute mania associated
with Bipolar I Disorder.
Pfizer's decision to discontinue its participation in the asenapine
development program is an outcome of a commercial analysis of the compound
as a part of its overall portfolio. Pfizer will return all product rights,
intellectual property and data to Organon and make orderly transitions
during 2007.
Organon will continue to develop asenapine.
SOURCE Pfizer Inc
 back to top
Related links:
http://www.pfizer.com
Photo Notes:A free corporate logo to accompany this
story is availableimmediately via Wieck Photo Database to any
media with telephoto receiver orelectronic darkroom, PC or
Macintosh, that can accept overhead transmissions.To retrieve a
logo, please call 972-392-0888./ /Company News On-Call:
http://www.prnewswire.com/comp/688250.html
Pfizer's press releases are available through PR Newswire's
Company News On-Call service on PRN's Web Site. Visit
http://www.prnewswire.com/comp/688250.html /
CONTACT:
Paul Fitzhenry, +1-212-733-4637 for Pfizer
Inc
|
